Orchid Pharma Ltd

Orchid Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Orchid Pharma Ltd

₹ 710 -0.25%
25 Jul - close price
orchidpharma.com BSE: 524372 NSE: ORCHPHARMA
About

Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. [1]

Key Points

Product Segments FY24
The company operates mainly in the Cephalosporins-based active pharmaceutical ingredients (API) business. These APIs are primarily used in anti-bacterial, anti-biotic, and anti-inflammatory formulations. [1][2]

Website BSE NSE
  • Market Cap ₹ 3,603 Cr.
  • Current Price ₹ 710
  • High / Low ₹ 1,998 / 604
  • Stock P/E 33.8
  • Book Value ₹ 261
  • Dividend Yield 0.00 %
  • ROCE 8.49 %
  • ROE 8.38 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has delivered good profit growth of 22.1% CAGR over last 5 years

Cons

  • Stock is trading at 2.72 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Tax rate seems low
  • Company has a low return on equity of 7.31% over last 3 years.
  • Promoter holding has decreased over last 3 years: -20.1%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE SmallCap BSE Allcap Nifty Microcap 250 Nifty Total Market

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
180 131 165 160 210 183 199 221 217 244 223 217 237
151 119 147 146 170 161 175 185 188 211 193 191 203
Operating Profit 29 12 18 14 40 22 24 36 29 33 30 26 34
OPM % 16% 10% 11% 9% 19% 12% 12% 16% 13% 14% 13% 12% 14%
-0 3 6 9 40 2 8 7 13 8 8 10 6
Interest 4 8 9 8 7 6 4 4 3 3 3 4 4
Depreciation 27 22 18 8 7 8 8 9 8 8 9 9 9
Profit before tax -2 -14 -3 7 65 11 20 31 30 29 26 24 28
Tax % 0% 0% 0% 0% 0% 0% 0% 0% -11% 0% 0% 0% 0%
-2 -14 -3 7 65 11 20 31 33 29 26 24 28
EPS in Rs -0.44 -3.45 -0.81 1.65 15.89 2.13 3.99 6.02 6.54 5.74 5.05 4.71 5.49
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Sep 2013 18m Mar 2015 18m Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
1,907 1,736 879 755 644 584 481 451 557 666 819 922
1,767 1,416 705 740 622 590 470 392 498 581 708 798
Operating Profit 140 320 174 15 22 -6 11 59 59 84 111 124
OPM % 7% 18% 20% 2% 3% -1% 2% 13% 11% 13% 14% 13%
81 156 -28 -59 20 42 -37 -15 57 57 30 32
Interest 520 537 294 347 310 7 6 52 33 33 17 15
Depreciation 244 321 143 146 133 130 118 109 87 55 33 34
Profit before tax -544 -383 -292 -537 -401 -101 -150 -117 -5 54 92 106
Tax % -2% -50% -6% -9% -12% 0% 0% 0% 0% 0% -4% 0%
-530 -191 -274 -489 -355 -101 -150 -117 -5 54 95 106
EPS in Rs -75.26 -22.41 -30.83 -54.91 -39.94 -11.36 -36.71 -28.70 -1.18 13.28 18.68 20.99
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -6%
5 Years: 14%
3 Years: 18%
TTM: 13%
Compounded Profit Growth
10 Years: 9%
5 Years: 22%
3 Years: 180%
TTM: 12%
Stock Price CAGR
10 Years: 27%
5 Years: %
3 Years: 30%
1 Year: -50%
Return on Equity
10 Years: %
5 Years: 2%
3 Years: 7%
Last Year: 8%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Sep 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 70 85 89 89 89 89 41 41 41 41 51 51
Reserves 418 354 82 -432 -763 -844 757 641 637 691 1,168 1,273
3,204 3,211 3,214 3,106 3,202 3,230 566 453 268 331 135 175
1,031 506 577 595 683 518 86 90 148 160 199 198
Total Liabilities 4,723 4,156 3,963 3,358 3,211 2,993 1,450 1,224 1,094 1,223 1,552 1,697
2,483 1,697 1,540 1,402 1,291 1,161 858 670 584 573 616 629
CWIP 360 282 280 288 272 278 26 7 10 46 24 28
Investments 124 125 125 125 125 0 0 15 49 50 69 178
1,756 2,053 2,017 1,543 1,523 1,553 566 531 452 554 842 862
Total Assets 4,723 4,156 3,963 3,358 3,211 2,993 1,450 1,224 1,094 1,223 1,552 1,697

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Sep 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
175 -370 211 402 6 15 80 24 90 13 131 27
-998 1,334 -1 -176 -28 45 167 67 113 -27 -316 -37
676 -597 -287 -465 33 -0 -250 -165 -217 31 167 25
Net Cash Flow -147 367 -76 -239 11 60 -3 -73 -14 18 -18 16

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Sep 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 35 61 156 101 82 88 50 107 105 116 84 96
Inventory Days 190 113 183 196 204 219 257 240 201 217 199 219
Days Payable 214 138 307 410 361 354 110 109 140 130 135 114
Cash Conversion Cycle 12 36 32 -113 -74 -47 197 237 165 204 148 200
Working Capital Days -99 104 136 -214 -508 -724 197 350 160 179 147 169
ROCE % -2% 1% 2% -3% -3% -5% -4% -4% -2% 5% 9% 8%

Shareholding Pattern

Numbers in percentages

1 Recently
Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
89.96% 89.96% 89.96% 72.40% 72.40% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84% 69.84%
1.37% 0.86% 0.81% 8.58% 8.08% 4.14% 1.96% 1.42% 1.94% 2.53% 2.69% 1.39%
2.98% 3.94% 2.62% 13.48% 12.46% 14.51% 17.73% 18.93% 18.30% 19.00% 20.10% 19.43%
5.69% 5.22% 6.60% 5.54% 7.05% 11.52% 10.47% 9.82% 9.94% 8.63% 7.37% 9.34%
No. of Shareholders 32,71730,89429,52329,13229,19736,93136,72034,69536,36334,15834,30339,827

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls